• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Allergy >Past, present, and future for biologic intervention in atopic dermatitis
【24h】

Past, present, and future for biologic intervention in atopic dermatitis

机译：生物治疗特应性皮炎的过去，现在和将来

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Atopic dermatitis (AD) is a debilitating disease that significantly alters the quality of life for one in four children and one in 10 adults. Current management of AD utilizes combinations of treatments to symptomatically alleviate disease by suppressing the inflammatory response and restoring barrier function in the skin, reducing disease exacerbation and flare, and preventing secondary skin infections. Resolution is temporary and long-term usage of these treatments can be associated with significant side-effects. Antibody therapies previously approved for inflammatory diseases have been opportunistically evaluated in patients with atopic dermatitis; however, they often failed to demonstrate a significant clinical benefit. Monoclonal antibodies currently in development offer hope to those individuals suffering from the disease by specifically targeting immune and molecular pathways important for the pathogenesis of atopic dermatitis. Here, we review the underlying biological pathways and the state of the art in therapeutics in AD.
机译：特应性皮炎（AD）是一种使人衰弱的疾病，它极大地改变了四分之一的儿童和十分之一的成年人的生活质量。当前对AD的管理通过抑制炎症反应和恢复皮肤中的屏障功能，减少疾病加重和发作，以及预防继发性皮肤感染，利用治疗的组合来对症缓解疾病。解决方法是暂时的，长期使用这些疗法可能会带来明显的副作用。先前已批准用于炎症性疾病的抗体疗法已在特应性皮炎患者中进行了机会性评估。然而，他们常常未能证明具有明显的临床益处。当前正在开发的单克隆抗体通过特异性靶向对特应性皮炎的发病机理重要的免疫和分子途径，为那些患有该疾病的人提供了希望。在这里，我们回顾了AD治疗中的潜在生物学途径和最新技术。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号